General Information


We are a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses. Our proprietary Avedro Corneal Remodeling Platform is designed to strengthen, stabilize and reshape the cornea utilizing corneal cross-linking in minimally invasive and non-invasive outpatient procedures to treat corneal ectatic disorders and correct refractive conditions, which are caused by changes in the shape of the eye that prevent light from focusing on the retina, causing blurred vision.

Employees: 122
Founded: 2002
Contact Information
Address 201 Jones Road, Waltham, MA 02451, US
Phone Number (781) 768-3400
Web Address http://www.avedro.com
View Prospectus: Avedro
Financial Information
Market Cap $255.9mil
Revenues $24.0 mil (last 12 months)
Net Income $-25.4 mil (last 12 months)
IPO Profile
Symbol AVDR
Exchange NASDAQ
Shares (millions): 5.0
Price range $14.00 - $14.00
Est. $ Volume $70.0 mil
Manager / Joint Managers BofA Securities/ J.P. Morgan
CO-Managers Cowen and Company/ Guggenheim Securities/ SVB Leerink
Expected To Trade: 2/14/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change